Aripiprazole
Product Images NDC 17856-0570

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 17856-0570). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (17856 0570 01)

Label for Aripiprazole oral solution, 5mg/5mL, packaged in 72 cups. The label includes storage instructions at 25°C with permitted excursions and warnings to keep out of reach of children. It provides the NDC 17856-0570, GTIN, expiration date, lot number, and contact information for reorder. Distributed by Atlantic Biologicals Corp.*

FDA Label Image

17856 0570 02

Aripiprazole oral solution 5 mg per 5 mL, delivers 5 mL per dose. The label shows storage instructions at 25°C (77°F), with permitted excursions between 15 to 30°C (59 to 86°F). Packaged by Unit Dose Solutions and distributed by Atlantic Biologicals Corp. The package quantity is 48 ENFit syringes. Includes barcodes, a QR code, lot number, expiration date 09/12/21, and a reorder phone number.*

FDA Label Image

Structure (Aripiprazole Oral Solution 1)

Chemical structure of aripiprazole showing its molecular framework including two chlorine atoms, a piperazine ring, and a quinolinone moiety, illustrating the spatial arrangement of the active ingredient.*

FDA Label Image

Figure 1 (Aripiprazole Oral Solution 2)

A chart titled 'The effects of other drugs on aripiprazole pharmacokinetics' showing aripiprazole fold change with 90% confidence intervals for different interacting drugs. The y-axis lists CYP3A4 Inhibitor ketoconazole, CYP2D6 Inhibitor quinidine, CYP3A4 Inducer carbamazepine, Gastric Acid Blockers famotidine, and others like valproate, lithium, and lorazepam. The x-axis presents change relative to reference without interacting drug, illustrating effects on AUC and Cmax pharmacokinetic parameters.*

FDA Label Image

Figure 2 (Aripiprazole Oral Solution 3)

A horizontal bar graph titled 'The effects of other drugs on dehydro-aripiprazole pharmacokinetics.' The chart displays fold changes in AUC and Cmax of dehydro-aripiprazole relative to a reference without interacting drugs. It compares effects from CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (tamotidine), and other drugs including valproate, lithium, and lorazepam. Error bars indicate 90% confidence intervals for the fold changes.*

FDA Label Image

Figure 3 (Aripiprazole Oral Solution 4)

A pharmacokinetic chart titled 'The effects of Aripiprazole on pharmacokinetics of other drugs' showing fold changes and 90% confidence intervals for various drugs including dextromethorphan, S-warfarin, R-warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The x-axis represents change relative to reference without interacting drug, ranging from 0.0 to 3.0.*

FDA Label Image

Figure 4 (Aripiprazole Oral Solution 5)

A figure titled 'Effects of intrinsic factors on aripiprazole pharmacokinetics' showing a horizontal forest plot chart. The chart compares fold changes and 90% confidence intervals of aripiprazole pharmacokinetic parameters (AUC, Cmax) across special populations such as CYP2D6 metabolizer status, gender, age, hepatic impairment, and renal impairment. The x-axis is labeled 'Change Relative to Reference'.*

FDA Label Image

Figure 5 (Aripiprazole Oral Solution 6)

A pharmacokinetic (PK) chart displaying dehydro-aripiprazole fold change and 90% confidence intervals. The graph compares AUC and Cmax values relative to reference for factors including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment, with fold changes plotted along the x-axis.*

FDA Label Image

Figure 6 (Aripiprazole Oral Solution 7)

Kaplan-Meier plot showing the cumulative proportion of patients with relapse in a schizophrenia study over time. The graph compares relapse rates between Aripiprazole and placebo groups, with the x-axis representing days from randomization and the y-axis representing the proportion with relapse. The number of subjects at risk is listed below the x-axis for both treatment groups at different time points.*

FDA Label Image

Figure 7 (Aripiprazole Oral Solution 8)

A Kaplan-Meier curve showing the cumulative proportion of patients with relapse over days from randomization in a Bipolar Study 7. The graph compares relapse proportions between Aripiprazole and placebo groups, with the Aripiprazole group displaying a lower relapse proportion over time. A table below the x-axis lists the number of subjects at risk for both groups at various time points.*

FDA Label Image

Figure 8 (Aripiprazole Oral Solution 9)

A Kaplan-Meier curve chart showing the cumulative proportion of patients with relapse to any mood event in a bipolar study over days from randomization. The graph compares relapse proportions between Aripiprazole (solid line) and placebo (dashed line) groups, with subject risk numbers tabulated below the x-axis at multiple time points up to day 364.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.